ghk-cu copper peptide hair growth evidence review GHK Clinical Trial (2016) — Research Summary GHK Cu Peptide | Clinical

Retatrutide is at the Phase 3 stage, and the cagrilintide-plus-semaglutide combination CagriSema was reported to have a New Drug Application under FDA review, but a filing under review is not an approval

Mechanism: Acts as a signal peptide that modulates fibroblast activity, collagen and glycosaminoglycan synthesis, antioxidant signaling, and copper bioavailability [1][2]

Compounded injectable GHK-Cu is dispensed pursuant to a patient-specific prescription and is not an FDA-approved drug

RF microneedling is considered safer and more predictable for melanin-rich skin tones than ablative laser approaches, and combining it with GHK-Cu addresses both the structural deficit and the inflammatory component that often drives post-inflammatory hyperpigmentation in these patients

Sublingual troches / lozenges: 50200 mcg per troche, 12 times daily , dissolved between cheek and gum for 1520 minutes